Market Place
Sourcing Support
Vivus Commercializes QSIVA In Nordic Countries And Poland
07 Oct 2024 //
GLOBENEWSWIRE
QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032
03 Jan 2023 //
PR NEWSWIRE
ICER reaffirms Qsymia as most cost-effective obesity treatment in final report
31 Aug 2022 //
ENDPTS
FDA Approves Qsymia for Treating Teens With Obesity
29 Jun 2022 //
MEDSCAPE
Fighting obesity by attacking both food intake and energy burn
29 Jun 2019 //
FIERCE BIOTECH
In another misstep for Vivus, FDA`s promo police ding misleading Qsymia webpage
07 Jun 2019 //
FIERCE PHARMA
OPDP Issues Second Untitled Letter of 2019
30 May 2019 //
RAPS
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
11 Sep 2018 //
FORBES
UC San Diego researchers uncover root of leptin resistance
24 Aug 2018 //
ENDPTS
With debt looming, browbeaten diet pill maker Orexigen goes bankrupt
13 Mar 2018 //
ENDPTS
Enforcement Report - Week of September 20, 2017
20 Sep 2017 //
FDA
Future obesity drugs must provide improved efficacy & safety,says GBI Research
17 Dec 2015 //
CPHI-ONLINE
Vivus counts $25M in Q3 sales, $300M in debt
05 Nov 2015 //
FIERCE PHARMA
Icahn casts his eye on Vivus with tender offer for convertible notes
09 Sep 2015 //
FIERCE PHARMA
Brutal honesty in drug marketing? For obesity meds, it`s key to avoiding the `magic pill` trap
09 Jun 2015 //
FIERCE PHARMA MARKETING
Eisai predicts long-awaited operating profit rise for fiscal 2015
15 May 2015 //
FIERCE PHARMA
Vivus Files Lawsuit Against Teva For Infringement Of Qsymia Patents
16 Apr 2015 //
EIN NEWSDESK
Weight-Loss Drugs Seek Acceptance From Patients and Physicians
17 Mar 2015 //
THE WALL STREET JOURNAL
Surprise: Obesity Med Contrave Might Help CV Outcomes. Too Bad Orexigen Blabbed It
05 Mar 2015 //
FIERCE PHARMA
Novo Nordisk Puts 500 Saxenda Reps on U.S. Streets, Aiming for $1B in Weight-Loss Sales
26 Jan 2015 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.